ExoPTEN

Search documents
New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model
Globenewswire· 2025-07-08 20:24
Medium and high doses improved movement quality in up to 100% of the animals in a dose-dependent manner Figure 1- SCI motor function after different doses of ExoPTEN (A) Paw use detected by the CatWalk XT camera.(B-F) CatWalk XT gait analysis demonstrates dose-dependent functional improvement following ExoPTEN treatment:B – % of hindlimbs recorded by CatWalk XT gait analysis system, recording of prints by CatWalk XT requires minimal use of leg and weight support, improvement can be seen in a dose dependen ...
NurExone Strengthens Path to Clinical Trials for ExoPTEN with New Manufacturing Process Validation
Globenewswire· 2025-06-04 20:04
Company Is also Seeking Shareholder Approval of Amended and Restated Omnibus PlanTORONTO and HAIFA, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that on May 22, 2025, it presented new manufacturing process data at the 4th annual meeting of the Israeli Society for Extracellular Vesicles Research (“ISEVR”), a conference dedicated to cutting-edge exosome science. Additionally, the Company will seek sh ...
NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025
Globenewswire· 2025-05-08 20:04
TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce that its preclinical data on optic nerve regeneration study was presented today at the Annual Meeting of the Association for Research in Vision and Ophthalmology (“ARVO) in Salt Lake City Utah, the world's largest and most ...
NurExone Expands European Engagement with Investor Events in Germany and Switzerland
Globenewswire· 2025-05-02 20:05
TORONTO and HAIFA, Israel, May 02, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is deepening its engagement with the European financial and healthcare communities through participation in three upcoming events. This increased activity follows NurExone’s recent announcement of a potential third therapeutic indication for its ...